Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 11, 2026, 4:05 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Pepcid Clear all
Terminated Phase 3 Interventional Results available

Treatment of Long CoronaVirus Disease (COVID) (TLC) Feasibility Trial

NCT05946551
View directory record Official record
Conditions
COVID-19
Interventions
Cetirizine, Famotidine, Cetirizine Placebo, Famotidine Placebo
Drug
Lead sponsor
Emory University
Other
Eligibility
18 Years and older
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024
U.S. locations
4
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Jul 16, 2025 · Synced Sep 11, 2026, 4:05 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Assess the Effect of Itraconazole, Rifampin, and Acid-Reducing Agents on INCB161734 Pharmacokinetics When Administered Orally in Healthy Participants

NCT07018635
View directory record Official record
Conditions
Healthy Participants
Interventions
INCB161734, Itraconazole, Rifampin, Esomeprazole, Famotidine
Drug
Lead sponsor
Incyte Corporation
Industry
Eligibility
18 Years to 55 Years
Enrollment
63 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Nov 25, 2025 · Synced Sep 11, 2026, 4:05 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study to Assess the Pharmacokinetic Drug-Drug Interactions of Lemborexant When Coadministered With an Oral Contraceptive, Famotidine, or Fluconazole in Healthy Subjects

NCT03451110
View directory record Official record
Conditions
Healthy Subjects
Interventions
lemborexant, Loestrin, famotidine, fluconazole
Drug
Lead sponsor
Eisai Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
50 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Sep 5, 2018 · Synced Sep 11, 2026, 4:05 PM EDT
Completed Phase 2 Interventional Results available

Standard Infusion Carboplatin Versus Prophylactic Extended Infusion Carboplatin in Patients With Patients With Recurrent, Ovary, Fallopian Tube, and Primary Peritoneal Cancer

NCT01248962
View directory record Official record
Conditions
Ovarian Cancer, Fallopian Tube Cancer, Peritoneal Cancer
Interventions
carboplatin
Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
21 Years and older · Female only
Enrollment
146 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2018
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Oct 1, 2019 · Synced Sep 11, 2026, 4:05 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study in Healthy Male Subjects to Understand How Savolitinib Behaves Inside the Body (Pharmacokinetics) When Administered Alone and in Combination With Famotidine

NCT04179071
View directory record Official record
Conditions
Solid Tumours
Interventions
Savolitinib, Famotidine
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 65 Years · Male only
Enrollment
16 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2020
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 6, 2020 · Synced Sep 11, 2026, 4:05 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Evaluate the Bioequivalence Between Immediate Release Tablets and Minitablets of Deucravacitinib (BMS-986165), and the Effect of Food and pH on the Drug Levels of the Minitablets in Healthy Adults

NCT06851871
View directory record Official record
Conditions
Healthy Participants
Interventions
Deucravacitinib, Famotidine
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years to 55 Years
Enrollment
26 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Apr 28, 2025 · Synced Sep 11, 2026, 4:05 PM EDT
Recruiting Phase 1 Interventional Accepts healthy volunteers

Single and Multiple Dose Study to Evaluate Safety and Pharmacokinetics of BMS-986533 in Healthy Participants and Assessments of Food and pH Effects on Relative Bioavailability, and Drug-Drug Interaction Potential in Healthy Participants

NCT07629999
View directory record Official record
Conditions
Healthy Volunteers
Interventions
BMS-986533, Famotidine, Placebo, Dabigatran Etexilate, Rosuvastatin
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years to 55 Years
Enrollment
136 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2027
U.S. locations
1
States / cities
Lincoln, Nebraska
Source: ClinicalTrials.gov public record
Updated Jul 23, 2026 · Synced Sep 11, 2026, 4:05 PM EDT
Completed Phase 2 Interventional Results available

Prevention of Post-Cardiac Surgery Acute Kidney Injury by Proton Pump Inhibitor

NCT06154226
View directory record Official record
Conditions
Acute Kidney Injury
Interventions
Pantoprazole, Famotidine
Drug
Lead sponsor
The University of Texas Health Science Center, Houston
Other
Eligibility
18 Years to 90 Years
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Mar 9, 2026 · Synced Sep 11, 2026, 4:05 PM EDT
Completed Phase 4 Interventional

Drug Interaction Study of Famotidine and Atazanavir With Ritonavir in HIV-Infected Patients

NCT00384904
View directory record Official record
Conditions
HIV Infections
Interventions
Atazanavir/Ritonavir, Atazanavir/Ritonavir + Famotidine, Atazanavir/Ritonavir + Tenofovir Disproxil Fumrarate + Famotidine
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years to 65 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
3
States / cities
Voorhees Township, New Jersey • Chapel Hill, North Carolina • Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Feb 4, 2010 · Synced Sep 11, 2026, 4:05 PM EDT
Recruiting Phase 4 Interventional

Gastrointestinal Dysmotility on Aspiration Risk

NCT05455359
View directory record Official record
Conditions
Esophageal Motility Disorders, Gastric Motor Dysfunction, Aspiration Pneumonia, Gastro Esophageal Reflux
Interventions
Prucalopride, Famotidine
Drug
Lead sponsor
Boston Children's Hospital
Other
Eligibility
5 Years to 21 Years
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Aug 2, 2026 · Synced Sep 11, 2026, 4:05 PM EDT
Recruiting Phase 2 Interventional

A Phase II Study of Perioperative Paclitaxel in Patients With Gastric Adenocarcinoma and Carcinomatosis or Positive Cytology

NCT05977998
View directory record Official record
Conditions
Gastric Adenocarcinoma, Carcinomatosis
Interventions
Paclitaxel, Dexamethasone, Diphenhydramine, Famotidine
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2030
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated May 21, 2026 · Synced Sep 11, 2026, 4:05 PM EDT
Terminated Phase 1 Interventional Accepts healthy volunteers

A Study to Evaluate the Safety, Tolerability, Drug Levels, Food, Formulation, and pH Effects on Relative Absorption of BMS-986465 and Its Active Derivative BMS-986464 in Healthy Participants

NCT06144697
View directory record Official record
Conditions
Healthy Participants
Interventions
BMS-986465, Placebo, Pegasys, Famotidine
Drug · Other
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years to 55 Years
Enrollment
267 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024
U.S. locations
2
States / cities
Anaheim, California • Austin, Texas
Source: ClinicalTrials.gov public record
Updated Feb 5, 2025 · Synced Sep 11, 2026, 4:05 PM EDT
Terminated Phase 1Phase 2 Interventional Results available

Initiation of Acid Suppression Therapy Prospective Outcomes for Laryngomalacia

NCT04614974
View directory record Official record
Conditions
Laryngomalacia, Gastro Esophageal Reflux
Interventions
Famotidine, Speech Language Therapy
Drug · Other
Lead sponsor
Reema Padia
Other
Eligibility
0 Months to 6 Months
Enrollment
65 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jul 19, 2025 · Synced Sep 11, 2026, 4:05 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Preventative Delirium Protocol in Elderly Patients

NCT03541408
View directory record Official record
Conditions
Delirium
Interventions
Control, Preventative Delirium Protocol
Other
Lead sponsor
Rush University Medical Center
Other
Eligibility
65 Years to 89 Years
Enrollment
263 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2021
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Dec 11, 2022 · Synced Sep 11, 2026, 4:05 PM EDT
Terminated Phase 2 Interventional Results available

Antihistamines in Eosinophilic Esophagitis

NCT04248712
View directory record Official record
Conditions
Eosinophilic Esophagitis
Interventions
Famotidine, Loratadine, Placebo
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
1
States / cities
Jacksonville, Florida
Source: ClinicalTrials.gov public record
Updated Dec 19, 2022 · Synced Sep 11, 2026, 4:05 PM EDT
Active, not recruiting Phase 2 Interventional

I-SPY COVID-19 TRIAL: An Adaptive Platform Trial for Critically Ill Patients

NCT04488081
View directory record Official record
Conditions
COVID-19
Interventions
Remdesivir, Imatinib Mesylate, Dexamethasone, Cenicriviroc, Icatibant, Apremilast, dornase alfa, Celecoxib, Famotidine, IC14, Aviptadil, narsoplimab, Cyproheptadine, Cyclosporine
Drug · Biological
Lead sponsor
QuantumLeap Healthcare Collaborative
Other
Eligibility
18 Years and older
Enrollment
1,500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2030
U.S. locations
36
States / cities
Birmingham, Alabama • Davis, California • Irvine, California + 30 more
Source: ClinicalTrials.gov public record
Updated Mar 15, 2026 · Synced Sep 11, 2026, 4:05 PM EDT
Completed Phase 2 Interventional Results available

Famotidine vs Placebo for the Treatment of Non-Hospitalized Adults With COVID-19

NCT04724720
View directory record Official record
Conditions
Covid-19
Interventions
Famotidine, Placebo
Drug
Lead sponsor
Northwell Health
Other
Eligibility
18 Years and older
Enrollment
56 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
1
States / cities
Lake Success, New York
Source: ClinicalTrials.gov public record
Updated Jun 14, 2026 · Synced Sep 11, 2026, 4:05 PM EDT
Completed Phase 4 Interventional

Stress Ulcer Prophylaxis Versus Placebo in Critically Ill Infants With Congenital Heart Disease

NCT03667703
View directory record Official record
Conditions
Congenital Heart Disease, Upper Gastrointestinal Bleeding, Stress Ulcer, Infection
Interventions
Famotidine, Placebo
Drug
Lead sponsor
Boston Children's Hospital
Other
Eligibility
1 Minute to 12 Months
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Sep 20, 2022 · Synced Sep 11, 2026, 4:05 PM EDT
Completed Phase 4 Interventional Results available

Analgesia After Total Knee Arthroplasty: Peri-Articular Injection Versus Epidural + Femoral Nerve Blockade

NCT01335542
View directory record Official record
Conditions
Readiness to Discharge
Interventions
Peri-Articular Injection, Epidural Pathway (PCEA+FNB)
Procedure
Lead sponsor
Hospital for Special Surgery, New York
Other
Eligibility
18 Years to 85 Years
Enrollment
91 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Apr 13, 2022 · Synced Sep 11, 2026, 4:05 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Determine the Effect of Famotidine on the Drug Levels of BMS-986256 in Healthy Participants

NCT04941755
View directory record Official record
Conditions
Healthy Participants
Interventions
BMS-986256, Famotidine
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years to 55 Years
Enrollment
22 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Jan 20, 2022 · Synced Sep 11, 2026, 4:05 PM EDT
Completed Phase 2 Interventional Results available

Chemotherapy and Locoregional Therapy Trial (Surgery or Radiation) for Patients With Head and Neck Cancer

NCT03107182
View directory record Official record
Conditions
HPV-Related Squamous Cell Carcinoma, HNSCC
Interventions
nab-paclitaxel, Carboplatin, Nivolumab, Cisplatin, Hydroxyurea, 5-FU, Dexamethasone, Famotidine, Diphenhydramine, Paclitaxel, Transoral robotic surgery (TORS), Adjuvant RT, Chemoradiotherapy
Drug · Procedure · Radiation
Lead sponsor
University of Chicago
Other
Eligibility
18 Years and older
Enrollment
72 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2024
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated May 5, 2025 · Synced Sep 11, 2026, 4:05 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Pharmacokinetic and Safety Study of Cenicriviroc and Acid Reducing Agents When Dosed Alone or in Combination

NCT02684799
View directory record Official record
Conditions
Healthy
Interventions
Cenicriviroc, Omeprazole, Famotidine
Drug
Lead sponsor
Tobira Therapeutics, Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
48 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Nov 23, 2017 · Synced Sep 11, 2026, 4:05 PM EDT
Terminated Phase 4 Interventional Results available

Opioid Free vs. Standard Perioperative Pain Regimen for Anterior Cervical Discectomy and Fusion (ACDF) Surgery

NCT04990804
View directory record Official record
Conditions
Opioid Use, Spinal Diseases, Surgery--Complications, Surgery, Postoperative Pain
Interventions
Opioid Analgesic, Opioid-Free Postoperative Pain Regimen
Drug
Lead sponsor
Vanderbilt University Medical Center
Other
Eligibility
18 Years and older
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Jan 30, 2024 · Synced Sep 11, 2026, 4:05 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Examine the Effect of Omeprazole, Famotidine, and an Acidic Beverage on the Pharmacokinetics of Entinostat in Healthy Adult Subjects

NCT02922933
View directory record Official record
Conditions
Volunteers, Healthy Volunteers, Human Volunteers, Normal Volunteers
Interventions
entinostat, Omeprazole, Famotidine
Drug · Dietary Supplement
Lead sponsor
Syndax Pharmaceuticals
Industry
Eligibility
19 Years to 55 Years
Enrollment
66 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2017
U.S. locations
2
States / cities
Tempe, Arizona • Lincoln, Nebraska
Source: ClinicalTrials.gov public record
Updated Aug 15, 2018 · Synced Sep 11, 2026, 4:05 PM EDT